# Ncardia Services

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ncardia-services-b-v

- Industry: Biotechnology
- Headquarters: Netherlands
- Website: www.ncardia.com
- Total disclosed funding: $12M
- Latest round: Series B (Nov 17, 2017)
- Investors on record: 6

## About

Founded in 2010 by Shinya Yamanaka and Kazutoshi Takahashi, and based in Leiden, Netherlands, Ncardia Services B.V. was formed following the merger of Pluriomics B.V. and Axiogenesis AG. The firm operates as a stem cell drug discovery and development company. In November 2021, Ncardia Services B.V. raised USD 60 million in venture funding led by investor Kiniciti.

The company collaborates with biopharmaceutical businesses to develop new treatments for a variety of modalities at any stage of development by utilizing the power of stem cell technologies in drug discovery and cell therapy. The business's focus is on the creation and production of human induced pluripotent stem cell (hiPSC)-derived goods and services for drug discovery, safety pharmacology, and disease modeling.

## Funding rounds

- Series B, Nov 17, 2017, $12M — Vesalius Biocapital, SFPI-FPIM, Sambrinvest, InnovationQuarter, Epimede, SRIW

## Investors

- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series B
- SFPI-FPIM — Series B
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series B
- InnovationQuarter (https://capitalatlas.ai/funds/innovationquarter) — Series B
- Epimede (https://capitalatlas.ai/funds/epimede) — Series B
- SRIW — Series B